BRPI0511519A - método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica - Google Patents
método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópicaInfo
- Publication number
- BRPI0511519A BRPI0511519A BRPI0511519-1A BRPI0511519A BRPI0511519A BR PI0511519 A BRPI0511519 A BR PI0511519A BR PI0511519 A BRPI0511519 A BR PI0511519A BR PI0511519 A BRPI0511519 A BR PI0511519A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- independently hydrogen
- preventing
- topical composition
- symptoms
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000024891 symptom Diseases 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title abstract 2
- 238000004806 packaging method and process Methods 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 239000002674 ointment Substances 0.000 abstract 2
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- -1 mists Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000006072 paste Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57414204P | 2004-05-25 | 2004-05-25 | |
| US10/853,585 US7439241B2 (en) | 2003-05-27 | 2004-05-25 | Compounds, formulations, and methods for treating or preventing rosacea |
| PCT/US2005/018288 WO2005115395A2 (en) | 2004-05-25 | 2005-05-25 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511519A true BRPI0511519A (pt) | 2007-12-26 |
Family
ID=35451386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511519-1A BRPI0511519A (pt) | 2004-05-25 | 2005-05-25 | método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2481412B1 (enExample) |
| JP (2) | JP4955543B2 (enExample) |
| KR (1) | KR101257046B1 (enExample) |
| CN (2) | CN101426502A (enExample) |
| AU (1) | AU2005247467B2 (enExample) |
| BR (1) | BRPI0511519A (enExample) |
| CA (2) | CA2567401C (enExample) |
| DK (1) | DK1761266T3 (enExample) |
| ES (2) | ES2647618T3 (enExample) |
| MX (1) | MXPA06013649A (enExample) |
| NZ (1) | NZ552325A (enExample) |
| PL (1) | PL1761266T3 (enExample) |
| PT (1) | PT1761266E (enExample) |
| SI (1) | SI1761266T1 (enExample) |
| WO (1) | WO2005115395A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| GB0611241D0 (en) * | 2006-06-07 | 2006-07-19 | Daniolabs Ltd | The treatment of increased sebum production |
| EP2493309A4 (en) * | 2009-10-26 | 2013-05-01 | Galderma Pharma Sa | METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA |
| EP2329849B1 (en) * | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| MX2012010824A (es) | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
| RU2535008C2 (ru) | 2010-03-26 | 2014-12-10 | Галдерма Ресерч Энд Девелопмент | Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии |
| US8492422B2 (en) | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
| US20120082625A1 (en) * | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| CA2814975A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel composition |
| SG189896A1 (en) * | 2010-10-21 | 2013-06-28 | Galderma Sa | Brimonidine gel compositions and methods of use |
| CN101972272B (zh) * | 2010-10-31 | 2012-07-04 | 无锡龙腾画材有限公司 | 一种二氧化氯皮肤凝胶及其制备方法 |
| JP2013542991A (ja) * | 2010-11-16 | 2013-11-28 | アラーガン インコーポレイテッド | （３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル）メタノールを含む医薬組成物 |
| AU2012217858A1 (en) * | 2011-02-15 | 2013-09-05 | Allergan, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| FR2977493B1 (fr) * | 2011-07-05 | 2014-02-14 | Galderma Res & Dev | Nouvelle composition anesthesique stable pour la reduction des reactions cutanees |
| BR112014009210A2 (pt) * | 2011-10-19 | 2017-04-18 | Galderma Sa | método para a redução da vermelhidão facial cutânea |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
| AU2014262960A1 (en) * | 2013-05-06 | 2015-11-26 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| AU2014292879A1 (en) * | 2013-07-26 | 2016-02-11 | Galderma Research & Development | Compositions for treating skin thickening |
| CN105764496B (zh) | 2013-10-07 | 2020-09-25 | 帝国制药美国公司 | 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物 |
| TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| TWI709417B (zh) | 2013-10-07 | 2020-11-11 | 美商帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| JP6659819B2 (ja) * | 2015-07-09 | 2020-03-04 | ガルデルマ・ソシエテ・アノニム | 化学療法に関連する脱毛の軽減方法 |
| JP2017052723A (ja) * | 2015-09-10 | 2017-03-16 | 株式会社Ｌｔｔバイオファーマ | ドライアイ改善剤 |
| CN106727462B (zh) * | 2016-11-14 | 2019-04-09 | 四川省人民医院 | 一种治疗面部皮炎的药物及其应用 |
| SG11202106716RA (en) * | 2019-01-12 | 2021-07-29 | Cellix Bio Private Ltd | Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof |
| US20220218590A1 (en) * | 2019-05-14 | 2022-07-14 | Abend Fritz Ventures Llc | Compositions and methods for removal of skin adhesive patches, products, and residual adhesives |
| JP2023539595A (ja) * | 2020-08-26 | 2023-09-15 | オティカラ，インコーポレーテッド | 鼻、耳及び他の組織の感染症及び／又は炎症を処置するための組成物、デバイス及び方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US4164570A (en) * | 1973-09-24 | 1979-08-14 | David Clough | Stabilized aqueous catecholamine solutions |
| US4285967A (en) * | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
| US4256763A (en) * | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4908387A (en) * | 1988-06-06 | 1990-03-13 | The Regents Of The University Of California | Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| IT1252692B (it) * | 1991-11-27 | 1995-06-23 | Zambon Spa | Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5720962A (en) * | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
| US6441047B2 (en) * | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| US5910312A (en) * | 1996-10-09 | 1999-06-08 | Ideal Ideas, Inc. | Acne treatment composition with vasoconstrictor |
| US5916574A (en) | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
| JPH1129482A (ja) * | 1997-05-14 | 1999-02-02 | Taisho Pharmaceut Co Ltd | 医薬組成物 |
| PL340711A1 (en) * | 1997-11-24 | 2001-02-26 | Procter & Gamble | Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability |
| US6159944A (en) * | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
| IN185228B (enExample) | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
| US20020197300A1 (en) * | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
| US6284765B1 (en) * | 2000-04-27 | 2001-09-04 | The University Of North Texas Health Science Center At Fort Worth | (+) naloxone and epinephrine combination therapy |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| CA2402405C (en) * | 2000-07-14 | 2008-02-12 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| JP3520076B2 (ja) * | 2001-10-02 | 2004-04-19 | 憲司 中村 | 皮膚外用剤 |
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
-
2005
- 2005-05-25 CA CA2567401A patent/CA2567401C/en not_active Expired - Fee Related
- 2005-05-25 CN CNA2005800223827A patent/CN101426502A/zh active Pending
- 2005-05-25 PL PL05754754T patent/PL1761266T3/pl unknown
- 2005-05-25 DK DK05754754.9T patent/DK1761266T3/da active
- 2005-05-25 PT PT57547549T patent/PT1761266E/pt unknown
- 2005-05-25 WO PCT/US2005/018288 patent/WO2005115395A2/en not_active Ceased
- 2005-05-25 ES ES12165557.5T patent/ES2647618T3/es not_active Expired - Lifetime
- 2005-05-25 JP JP2007515279A patent/JP4955543B2/ja not_active Expired - Fee Related
- 2005-05-25 CN CN201410590016.2A patent/CN104490884A/zh active Pending
- 2005-05-25 KR KR1020067027124A patent/KR101257046B1/ko not_active Expired - Fee Related
- 2005-05-25 EP EP12165557.5A patent/EP2481412B1/en not_active Expired - Lifetime
- 2005-05-25 ES ES05754754T patent/ES2424644T3/es not_active Expired - Lifetime
- 2005-05-25 EP EP05754754.9A patent/EP1761266B1/en not_active Expired - Lifetime
- 2005-05-25 NZ NZ552325A patent/NZ552325A/en not_active IP Right Cessation
- 2005-05-25 SI SI200531745T patent/SI1761266T1/sl unknown
- 2005-05-25 BR BRPI0511519-1A patent/BRPI0511519A/pt not_active Application Discontinuation
- 2005-05-25 CA CA2824612A patent/CA2824612C/en not_active Expired - Fee Related
- 2005-05-25 MX MXPA06013649A patent/MXPA06013649A/es not_active Application Discontinuation
- 2005-05-25 AU AU2005247467A patent/AU2005247467B2/en not_active Ceased
-
2011
- 2011-12-01 JP JP2011263425A patent/JP5547705B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN104490884A (zh) | 2015-04-08 |
| PL1761266T3 (pl) | 2013-09-30 |
| DK1761266T3 (da) | 2013-08-05 |
| KR20070032716A (ko) | 2007-03-22 |
| AU2005247467A1 (en) | 2005-12-08 |
| CA2824612A1 (en) | 2005-12-08 |
| JP4955543B2 (ja) | 2012-06-20 |
| EP2481412B1 (en) | 2017-09-27 |
| EP1761266B1 (en) | 2013-05-08 |
| PT1761266E (pt) | 2013-06-04 |
| JP2012072176A (ja) | 2012-04-12 |
| MXPA06013649A (es) | 2007-07-09 |
| KR101257046B1 (ko) | 2013-04-22 |
| SI1761266T1 (sl) | 2013-08-30 |
| CA2567401A1 (en) | 2005-12-08 |
| EP1761266A4 (en) | 2009-11-11 |
| ES2647618T3 (es) | 2017-12-22 |
| AU2005247467B2 (en) | 2010-12-02 |
| JP2008500356A (ja) | 2008-01-10 |
| CA2824612C (en) | 2016-08-16 |
| NZ552325A (en) | 2010-11-26 |
| WO2005115395A2 (en) | 2005-12-08 |
| JP5547705B2 (ja) | 2014-07-16 |
| CN101426502A (zh) | 2009-05-06 |
| CA2567401C (en) | 2013-11-12 |
| ES2424644T3 (es) | 2013-10-07 |
| EP1761266A2 (en) | 2007-03-14 |
| WO2005115395A3 (en) | 2009-04-09 |
| EP2481412A1 (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511519A (pt) | método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica | |
| WO2004105703A3 (en) | Compounds, formulations, and methods for treating or preventing rosacea | |
| NO20044763L (no) | 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander | |
| BR0207278A (pt) | Derivados de ftalazinona-piperidina como inibidores de pde4 | |
| BR0114913A (pt) | Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona | |
| BR0007229A (pt) | Aminoazaciclos heterocìclicos substituìdos úteis como agentes de sistema nervoso central | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| EP2513343A4 (en) | METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION | |
| BR112014015402A2 (pt) | composição sólida de cuidado pessoal, produto de cuidado pessoal e método de tratar cabelo e/ou pele | |
| BRPI0412130A (pt) | compostos tetracìclicos como inibidores de c-met | |
| BR9907847A (pt) | Agentes anti-inflamatórios seletivos para glucocorticóides | |
| BR9810396A (pt) | Processos para usar composições contendo imidazoldioxolano de diclorofenila para tratar dermatite seborréica, caspa, psorìase e acne, e composições dos mesmos | |
| BR0009838A (pt) | Dissulfetos cìclicos de pirrolidincarbonilamino | |
| BRPI0506792A (pt) | derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamação | |
| ES2165233T3 (es) | Empleo de 1-fosfato de esfingosina, derivados de 1-fosfato de esfingosina y/o sus mezclas para el tratamiento de enfermedades cutaneas inflamatorias. | |
| Costantino et al. | Anti-inflammatory activity of newly synthesized 2, 6-bis-(1, 1-dimethylethyl) phenol derivatives | |
| TW200612972A (en) | Essential oils for treating and/or preventing allergic disease | |
| BR0309551A (pt) | Derivados substituìdos de pirazina | |
| BR0109445A (pt) | Derivados de imidazol com atividade antiinflamatória | |
| BR9910587A (pt) | Uso de derivados de aril(ou heteroaril) azolilcarbinóis na fabricacão de um medicamento para tratamento de inflamação neurogênica | |
| DK1756066T3 (da) | Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet | |
| BR9915899A (pt) | Composto, composição farmacêutica e método para tratar ou inibir distúrbios associados com contração do músculo liso. | |
| ATE243695T1 (de) | 5-bicycloindolverbindungen | |
| BR0007449A (pt) | Produtos, composto, processo de preparação dos produtos, medicamentos, e, utilização dos produtos | |
| BRPI0509737A (pt) | glicosamina e pró-fármacos mútuos antiinflamatórios de glicosamina, composições, e métodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal: appeal against refusal |